

RealRate

PHARMACEUTICAL 2020

RENOVARO BIOSCIENCES INC. Rank 14 of 358







PHARMACEUTICAL 2020



RENOVARO BIOSCIENCES INC. Rank 14 of 358

The relative strengths and weaknesses of RENOVARO BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RENOVARO BIOSCIENCES INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 159% points. The greatest weakness of RENOVARO BIOSCIENCES INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 300%, being 263% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	12,495
Cost of Goods Sold	0
Intangible Assets	11,733
Liabilities, Current	1,110
Liabilities, Non-Current	0
Other Assets	154,962
Other Compr. Net Income	0
Other Expenses	220
Other Liabilities	5,667
Other Net Income	-7,026
Other Revenues	0
Property and Equipment	688
Research and Development	2,498
Selling, General and Administrative Expense	8,272

Output Variable	Value in 1000 USD
Assets	179,877
Liabilities	6,777
Expenses	10,990
Revenues	0
Stockholders Equity	173,100
Net Income	-18,016
Comprehensive Net Income	-18,016
Economic Capital Ratio	300%

